PrintFriendly

Print Friendly, PDF & Email

Genentech Response to NHF and HFA Questions Regarding Hemlibra

October 17, 2019
2019-10-Joint-Letter-Product-Safety-Issues

On October 16, 2019, Genentech sent the following letter to HFA and NHF. Genentech’s letter responds to questions posed in the joint HFA-NHF letter of October 11, regarding reports of particulate matter in vials of Hemlibra. HFA and NHF will keep the bleeding disorders community informed as further information develops.

Please note that HFA and NHF do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.